ANNX
HEALTHCAREAnnexon Inc
$5.70-0.02 (-0.35%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ANNX Today?
No stock-specific AI insight has been generated for ANNX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.60$7.18
$5.70
Fundamentals
Market Cap$926M
P/E Ratio—
EPS$-1.34
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding162.5M
ANNX News
20 articles- Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated MilestonesYahoo Finance·May 7, 2026
- Annexon to Present at the Bank of America Securities Health Care Conference 2026Yahoo Finance·May 6, 2026
- Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside PotentialYahoo Finance·Apr 27, 2026
- Annexon Biosciences (ANNX) Buy Rating RetainedYahoo Finance·Apr 21, 2026
- Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA FilingMarketbeat·Apr 15, 2026
- Annexon to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 8, 2026
- Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?Yahoo Finance·Apr 1, 2026
- Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Apr 1, 2026
- Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesYahoo Finance·Mar 30, 2026
- Are Medical Stocks Lagging American Well (AMWL) This Year?Yahoo Finance·Mar 23, 2026
- Annexon Investor Day: ANX007 Targets C1q in Dry AMD GA as Phase III Readout Nears Q4Marketbeat·Mar 19, 2026
- Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 16, 2026
- Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen ConferenceMarketbeat·Mar 4, 2026
- Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 24, 2026
- Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic AtrophyYahoo Finance·Feb 17, 2026
- Does Annexon’s EMA Filing For Tanruprubart Reshape The Bull Case For ANNX?Yahoo Finance·Jan 20, 2026
- Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre SyndromeYahoo Finance·Jan 18, 2026
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jan 16, 2026
- Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings AheadMarketbeat·Jan 14, 2026
- Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026Yahoo Finance·Jan 12, 2026
All 20 articles loaded
Price Data
Open$5.80
Previous Close$5.72
Day High$5.82
Day Low$5.65
52 Week High$7.18
52 Week Low$1.60
52-Week Range
$1.60$7.18
$5.70
Fundamentals
Market Cap$926M
P/E Ratio—
EPS$-1.34
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding162.5M
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—